Concord Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹326.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.39 per cent from ₹277.77 crore. This corresponds to a year-on-year *(YoY) decline of 24.15 per cent.
Operating Profit
Operating Profit stands at ₹118.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 24.57 per cent from ₹95.01 crore. This corresponds to a year-on-year *(YoY) decline of 37.34 per cent.
PBDT
PBDT stands at ₹133.62 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.37 per cent from ₹104.91 crore. This corresponds to a year-on-year *(YoY) decline of 32.57 per cent.
Profit Before Tax
Profit Before Tax stands at ₹114.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 32.40 per cent from ₹86.16 crore. This corresponds to a year-on-year *(YoY) decline of 37.85 per cent.
Net Profit
Net Profit stands at ₹88.47 crore, reflecting a quarter-on-quarter *(QoQ) increase of 39.02 per cent from ₹63.64 crore. This represents a 36.98 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Concord Biotech Ltd News
Concord Biotech Ltd Earnings
- YOY
- QOQ
Concord Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Concord Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Concord Biotech Ltd Financial Reports
Concord Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Concord Biotech | 6.79% | 7.00% | 3.83% | 11.79% | 17.17% | -24.55% |
| Cohance Life | 0.94% | 2.97% | -4.72% | -8.50% | 16.22% | -56.89% |
| Alembic Pharma | -0.90% | 1.90% | -1.93% | 6.11% | 3.32% | -17.01% |
| Jubilant Pharmo | 1.34% | 1.65% | 0.45% | 5.11% | 1.30% | -18.04% |
| Alivus Life | 2.46% | 2.56% | -0.39% | 5.80% | 23.41% | 9.66% |
| Corona Remedies | 1.82% | -0.79% | 6.97% | 21.15% | 44.87% | 45.94% |
| Shilpa Medicare | 0.20% | -0.08% | 6.25% | 44.85% | 111.03% | 37.26% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : SUDHIR JAIRAM VAID
ED / Joint MD / CEO / Promoter : ANKUR VAID
Non-Exec & Non-Independent Dir : Ravi Kapoor
Non-Exec & Non-Independent Dir : Rajiv Agarwal
Independent Non Exe. Director : BHARTI KHANNA
Independent Non Exe. Director : Amitabh Thakore
Independent Non Exe. Director : Arvind Agarwal
Independent Non Exe. Director : Jayaram Easwaran
Independent Non Exe. Director : Mandayam Chakravarthy Sriraman
Company Sec. & Compli. Officer : Paritosh Trivedi
Independent Non Exe. Director : EKTA GUPTA